FLUZONE HIGH-DOSE QUADRIVALENT
FLUZONE HIGH-DOSE QUADRIVALENT
Approved
DIN Number
02500523
Drug Class
Human
Market Date
Sep 17, 2021
Company
HC
Sanofi Pasteur Limited
Product Information
Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.
Product Details
Health Canada regulatory and product classification information
Regulatory Identifiers
DIN Number02500523
AIG Number0455410004
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D
A
ATC Code
J07BB02 INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN
Product Specifications
Dosage FormSuspension
Route of AdministrationIntramuscular
AHFS Classification80:12.00
Health Canada Classification
ACTIVE INGREDIENTS (4)
HAEMAGGLUTININ-STRAIN A (H1N1)Active
Strength: 60 MCG / 0.7 ML
Monograph: HAEMAGGLUTININ-STRAIN A (H1N1)
HAEMAGGLUTININ-STRAIN A (H3N2)Active
Strength: 60 MCG / 0.7 ML
Monograph: HAEMAGGLUTININ-STRAIN A (H3N2)
HAEMAGGLUTININ-STRAIN B (VICTORIA)Active
Strength: 60 MCG / 0.7 ML
Monograph: HAEMAGGLUTININ-STRAIN B (VICTORIA)
HAEMAGGLUTININ-STRAIN B (YAMAGATA)Active
Strength: 60 MCG / 0.7 ML
Monograph: HAEMAGGLUTININ-STRAIN B (YAMAGATA)